KDC-MN-1336 – Kodiac biolabs

Our opinion on this compoundNiche research probe

55/100

First-in-class zonulin antagonist with a clean mechanism and unique bench utility, hurt badly by a 2022 Phase 3 miss

Look, larazotide occupies a genuinely unusual position in the research peptide landscape. Its mechanism is specific in a way that most gut-targeted peptides arent: it competes at the zonulin receptor and blocks ZOT/zonulin-driven tight junction disassembly without touching baseline junctional integrity. That selectivity is not a marketing angle, it comes from Alessio Fasanos group at Maryland building off the structural homology between the Vibrio cholerae ZOT toxin and pre-haptoglobin 2, the endogenous zonulin ligand. No other compound available to investigators does this specific thing at the receptor level.

The problem is the 2022 CeDLara Phase 3 readout. 9 Meters Biopharma ran a well-powered trial targeting symptomatic celiac patients on a gluten-free diet who still experience residual symptoms, presumably from gluten cross-contamination driving tight junction disruption. The primary endpoint, a celiac disease patient-reported outcome score, didnt move. That is a real failure and we’re not going to dress it up. Secondary analyses showed some biological signal, and the compound clearly reached its target (gut-luminal exposure is the whole point of an unabsorbed oral peptide), but the field is right to read this as a setback for the celiac indication specifically.

What keeps larazotide interesting as a research compound is that the mechanism failure hypothesis hasnt been established. The Phase 3 miss is more plausibly a trial design and endpoint selection problem than a biology problem. The leaky-gut phenotype in symptomatic celiac on GFD is heterogeneous, and PRO endpoints in that population are notoriously noisy. The tight junction dysregulation story in IBD, multiple sclerosis, and type 1 diabetes is mechanistically distinct from celiac and remains under active investigation. Larazotide is the only tool that lets you ask what happens when you specifically block the zonulin arm of tight junction opening in those contexts, in vivo, without the off-target pharmacology that comes with broader TJ modulators.

For a bench program focused on intestinal barrier function, this compound has real probe value. The zero systemic absorption profile is actually an asset: you can dose luminally and confine your intervention to the gut without worrying about peripheral effects, which makes attribution cleaner. We think the strongest use cases right now are gut-permeability models in autoimmune disease contexts where the zonulin axis has a plausible mechanistic role, not celiac disease per se. Evidence quality is solid for a research peptide, multiple Phase 2 trials with real data, but the Phase 3 failure and the narrow indication space keep the overall compelling-target score in the mid-50s. Honest assessment: this is a niche tool, not a headline compound, but for the right program its the only tool that fits.

Novelty: 48
Mechanism promise: 58
In-category differentiation: 68
Evidence quality: 55
Translational signal: 35
Research bench value: 65

Rationale Larazotide earns above-average differentiation because it remains the only specific pharmacological tool for probing the zonulin/tight junction axis in vivo and in ex vivo intestinal models; the Phase 3 failure in celiac disease (CeDLara, 2022) drags translational signal sharply down but does not disprove the mechanism, which is intact and still relevant in IBD, MS, and barrier-dysfunction research.

Zonulin antagonist octapeptide and tight junction modulator

An eight-residue zonulin receptor antagonist developed by Innovate Biopharmaceuticals (now 9 Meters Biopharma) as the first specific gut tight junction modulator advanced to Phase 3 in celiac disease.

Abstract

Larazotide acetate (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly; CAS 258818-34-7; molecular weight 754.86 free peptide) is an eight-residue synthetic peptide developed at the University of Maryland by Alessio Fasano and colleagues as a competitive antagonist at the zonulin receptor. Zonulin (also designated pre-haptoglobin 2) is the human ortholog of the Vibrio cholerae zonula occludens toxin (ZOT) and is the only known endogenous regulator of intestinal epithelial tight junction permeability; activation of the zonulin pathway in response to gluten exposure or other triggers produces transient opening of intestinal tight junctions and translocation of luminal antigens into the lamina propria, contributing to celiac disease pathogenesis and a broader leaky-gut phenotype implicated in autoimmune and inflammatory conditions. Larazotide binds the zonulin receptor and blocks ZOT/zonulin-induced tight junction disassembly without directly affecting baseline tight junction integrity. The compound was advanced through Phase 1 and Phase 2 trials in celiac disease and entered Phase 3 (CeDLara) for the residual gluten-cross-contamination phenotype in patients on a gluten-free diet who continue to experience symptoms. The Phase 3 readout in 2022 did not meet the primary endpoint of celiac disease patient-reported outcome, and 9 Meters Biopharma announced discontinuation of the program. Despite the clinical setback in celiac disease, larazotide remains a pharmacologically distinct research tool for tight junction modulation in inflammatory bowel disease, multiple sclerosis, and other indications where intestinal barrier dysfunction is implicated. Oral bioavailability is essentially zero (the peptide acts in the gut lumen and is not absorbed); the route of administration is per oral as a sustained-release formulation. Adverse events in clinical trials were mild and dominated by gastrointestinal effects.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1336Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-1336

Larazotide

Abstract

Read the full monograph